Akari Therapeutics (FRA:CLA) Land And Improvements : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Land And Improvements?

Akari Therapeutics's land and improvements for the quarter that ended in Mar. 2025 was €0.00 Mil.

Akari Therapeutics Land And Improvements Historical Data

The historical data trend for Akari Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Land And Improvements Chart

Akari Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

Akari Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Akari Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Akari Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210

Website

https://www.akaritx.com

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.